LABU Trading Analysis - 10/23/2026 04:47 PM — TRU-SENTIMENT

News Headlines & Context

LABU is a 3x leveraged ETF tracking the S&P Biotechnology Select Industry Index, so it typically amplifies moves in small- and mid-cap biotech equities. Recent general-knowledge context for the product includes:

• Biotech sector faced broad de-risking through October 2026 as investors rotated out of high-beta names ahead of Fed commentary.
• Several mid-cap biotech firms delayed clinical trial readouts, reducing near-term catalysts and weighing on sector sentiment.
• Increased Treasury yields and a strong dollar pressured speculative biotech flows, indirectly dragging LABU lower.
• No specific LABU issuer earnings are scheduled, but underlying index rebalances can cause sharp intraday swings.

Contextually, the embedded data shows a clear downward drift into late October with bearish options flow, consistent with the sector-wide caution described above. This news context is separated from the strict data analysis below.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for LABU:

• Trailing P/E: null; Forward P/E: null; PEG ratio: null — no earnings-based valuation metrics available.
• Trailing EPS: null; Forward EPS: null — no recent earnings trend data.
• Revenue growth (YoY): null; profit margins (gross/operating/net): null.
• Debt/Equity: null; ROE: null; Free Cash Flow: null — not provided.
• Market cap: $510,350,400.00; shares outstanding: 2,324,000.00.
• Dividend yield: 0.39%; dividend rate: $0.91; ex-dividend: 2025-12-23.
• Beta: 3.16 (highly volatile vs market); 52-week high: $341.93, low: $108.90.
• Historical volatility: 96.51%; average volume: 441,000.00.
• Analyst consensus / target mean price: null (no analyst opinions provided).

Fundamentally, LABU shows no traditional equity fundamentals (as expected for a leveraged ETF) but exhibits extreme volatility (HV 96.51%, beta 3.16). This aligns with the weak technical and bearish sentiment picture rather than diverging from it.

Current Market Position

Current price per indicators: $220.23 (2026-10-23 close). From daily history, the stock closed at $220.23 on 2026-10-23 after opening at $222.63, ranging $210.64 to $224.50. Prior day (2026-10-22) closed $226.11. The 30-day range from indicators is high $293.10 / low $196.63.

Minute bars (2026-10-22 09:30 to 2026-10-23 15:55) show early strength on 10-22 (open $230.21, high $236.39 by 09:35) then deterioration; by 2026-10-23 15:55 close was $219.45, with late-session lows $219.45 and weak volume (2,786). Intraday momentum is downward with lower highs/lows into Friday close.

Technical Analysis

Price is below SMA 5 ($226.76), SMA 20 ($233.89), and SMA 50 ($266.83) — full bearish alignment, no golden cross. RSI 40.26 shows weak momentum, not yet oversold. MACD (-11.11) below signal (-8.89), histogram -2.22 confirms bearish momentum. Bollinger mid $233.89, price below mid, near lower band $195.78 (no squeeze, expansion downward). Price is in lower 23% of 30-day range ($196.63–$293.10).

True Sentiment Analysis (Delta 40-60 Options)

From embedded True Sentiment options data (2026-10-23):

Call Dollar Volume: $365,340.00 (35.7%) Put Dollar Volume: $656,980.00 (64.3%) Total: $1,022,320.00

Sentiment: Bearish. Pure directional conviction (Delta 40-60) shows put dominance with 64.3% put dollar vol vs 35.7% call. This aligns with bearish technicals (price below all SMAs, MACD neg). No divergence — both signal downside expectation.

Key Price Levels (Observational Only)